Waeber B, Brunner H R
Hypertension Division, University Hospital, Lausanne, Switzerland.
Br J Clin Pract. 1996 Jul-Aug;50(5):265-8.
Losartan is an orally active angiotensin II antangonist that selectively blocks effects mediated by the stimulation of the AT1 subtype of the angiotensin II receptor. This agent, at doses of 50-150mg/day, is as effective at lowering blood pressure as chronic angiotensin converting enzyme (ACE) inhibitors. Losartan is generally well tolerated and has an incidence of adverse effects very similar, in double-blind controlled trials, to that of placebo. It does not cause coughing, the most common side-effect of the ACE inhibitors, most probably because angiotensin II antagonism has no impact on ACE, an enzyme known to process bradykinin and other cough-inducing peptides. Losartan is a promising antihypertensive agent with the potential to become a first-line option for the treatment of patients with high blood pressure.
氯沙坦是一种口服有效的血管紧张素II拮抗剂，它能选择性地阻断由血管紧张素II受体1型（AT1）亚型刺激介导的效应。该药物剂量为每日50 - 150毫克时，在降低血压方面与慢性血管紧张素转换酶（ACE）抑制剂同样有效。氯沙坦一般耐受性良好，在双盲对照试验中，其不良反应发生率与安慰剂非常相似。它不会引起咳嗽，而咳嗽是ACE抑制剂最常见的副作用，这很可能是因为血管紧张素II拮抗作用对ACE没有影响，ACE是一种已知可处理缓激肽和其他诱导咳嗽肽的酶。氯沙坦是一种很有前景的抗高血压药物，有可能成为治疗高血压患者的一线选择。
